Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 15% IN WATER vs MANNITOL 15%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure before irreversible renal failure occurs
Reduction of intracranial pressure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Promotion of diuresis in oliguric phases of acute renal failure (off-label),Cerebral edema (off-label)
IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
Terminal elimination half-life is approximately 0.25–1.5 hours in patients with normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Minimal hepatic metabolism; excreted unchanged by the kidneys.
Mannitol is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration.
Primarily renal excretion as unchanged drug; >97% eliminated by glomerular filtration within 24 hours. Minimal biliary/fecal elimination (<3%).
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Negligible (<5%) protein binding; does not bind significantly to albumin or other plasma proteins.
Approximately 0-10% bound to plasma proteins (negligible binding).
Volume of distribution is approximately 0.4–0.6 L/kg, confined primarily to extracellular fluid; little intracellular penetration.
0.5-0.8 L/kg; primarily distributes in extracellular fluid (interstitial space).
Not applicable (NA) due to intravenous administration only; oral bioavailability is negligible (not absorbed).
Intravenous: 100% (only route used therapeutically); not administered orally due to minimal absorption (oral bioavailability < 5%).
Contraindicated in anuria or severe renal impairment (e GFR < 10 m L/min); use with caution in mild to moderate impairment, monitor serum osmolarity and renal function.
Contraindicated in anuria due to severe renal disease. For GFR <50 m L/min, use with caution and monitor serum osmolarity and renal function. No specific dose reduction defined; consider alternative therapy if GFR <20 m L/min.
No specific adjustment for Child-Pugh class; monitor for volume overload and electrolyte disturbances in severe hepatic impairment.
No specific adjustment for Child-Pugh class. Use with caution in ascites or severe hepatic impairment due to risk of volume overload and electrolyte disturbances.
IV infusion of 0.25-2 g/kg as a 15-20% solution over 30-60 minutes; dosing based on weight and clinical response.
0.25-1 g/kg (1.67-6.67 m L/kg of 15% solution) intravenously over 30-60 minutes. Repeat doses as needed based on clinical response, up to 1-2 g/kg.
Start at lower end of dosing range; monitor for fluid overload, electrolyte imbalances, and renal function due to age-related decreased reserve.
Initiate with lower doses (e.g., 0.5 g/kg) and titrate carefully due to increased risk of volume overload, electrolyte imbalance, and renal impairment. Monitor renal function, serum osmolarity, and fluid status closely.
None FDA-approved.
None
Renal toxicity with high doses or prolonged use,Congestive heart failure exacerbation due to volume expansion,Electrolyte disturbances (hyponatremia, hypokalemia),Rapid infusion may cause hypotension and seizures,Use with caution in patients with anuria or pre-existing renal disease
May cause volume expansion, pulmonary congestion, or heart failure in patients with cardiac dysfunction. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with renal impairment, as accumulation can cause metabolic acidosis. Risk of osmotic nephrosis or acute kidney injury with high doses or prolonged use. May exacerbate intracranial hemorrhage due to increased cerebral blood volume.
Anuria due to severe renal disease,Well-established anuria due to severe renal disease,Pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity to mannitol.
No specific food interactions are documented. However, patients should maintain adequate hydration unless contraindicated. Diets high in sodium may exacerbate hypernatremia risk. Monitor fluid and electrolyte intake as directed by the clinician.
No significant food interactions. Avoid excessive sodium intake to prevent fluid retention.
Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that can cause maternal osmotic diuresis and fluid/electrolyte disturbances, potentially affecting fetal homeostasis. Risk in first trimester is unknown; in second and third trimesters, use only if clearly needed due to potential for maternal pulmonary edema or heart failure.
Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimesters: Use only if clearly needed, as osmotic diuresis may cause fetal dehydration, electrolyte imbalances, or altered placental blood flow. There is no evidence of direct teratogenicity.
It is unknown if mannitol is excreted in breast milk. In lactating women, breast-feeding is not recommended during IV infusion of high-dose mannitol due to possible infant exposure to high osmolar load. M/P ratio not available.
Mannitol is not known to be excreted into human milk. M/P ratio is not established due to lack of data. Due to its high molecular weight and poor oral bioavailability, infant exposure via breastfeeding is likely negligible. Use with caution in lactating women only if clearly needed.
No specific dose adjustments for pregnancy are established. Use with caution due to potential for altered renal function and fluid balance. Start with lowest effective dose, such as 50-100 g over 24 hours. Monitor closely for maternal volume overload.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume and renal clearance) may require higher doses to achieve desired effect. Monitor clinical response and adjust dosing based on urine output and serum osmolality.
OSMITROL 15% IN WATER is a hypertonic solution for intravenous administration. Monitor serum sodium and osmolality closely to avoid hypernatremia and hyperosmolality. Ensure patency of IV line as extravasation can cause tissue necrosis. Use with caution in patients with renal impairment, heart failure, or hypovolemia. Rapid infusion can cause hemolysis. May cause osmotic diuresis leading to electrolyte depletion; monitor potassium and magnesium.
Monitor serum osmolality and electrolyte levels closely during therapy; use in cerebral edema requires maintaining serum osmolality 310-320 m Osm/L. Administer via in-line filter (0.22 micron) to prevent crystal emboli. Rapid infusion may cause transient hypervolemia; caution in heart failure or renal impairment. Onset of diuresis is 1-3 hours after IV administration.
This medication is given intravenously to reduce brain swelling or lower eye pressure.,Report any pain, redness, or swelling at the injection site immediately.,You may experience increased thirst or urination; this is expected due to the medication's effects.,Inform your healthcare provider if you have a history of kidney problems, heart failure, or dehydration.,Regular blood tests will be performed to monitor your electrolyte levels and kidney function.
This medication increases urine output to reduce fluid buildup.,Report any chest pain, difficulty breathing, or swelling in ankles/feet.,You may experience headache, nausea, or dry mouth.,Avoid excessive salt intake to prevent fluid retention.,Notify your doctor if you have kidney disease or heart conditions.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 15% IN WATER vs MANNITOL 15%, answered by our medical review team.
OSMITROL 15% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.. MANNITOL 15% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 15% IN WATER and MANNITOL 15% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 15% IN WATER is: IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.. The standard adult dose of MANNITOL 15% is: 1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 15% IN WATER and MANNITOL 15% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 15% IN WATER is classified as Category C. Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that . MANNITOL 15% is classified as Category A/B. Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.